Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Alcon Inc.
  6. News
  7. Summary
    ALC   CH0432492467

ALCON INC.

(ALC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Dry Eye Syndrome Market 2026|Industry Analysis with Top Manufacturers- Allergan, Alcon, Santen Pharmaceutical Co. Ltd., Shire/SAR code Bioscience, Otsuka Holdings

07/01/2021 | 04:32am EDT

Dry Eye Syndrome Market 2026 | Industry Analysis with Top Manufacturers- Allergan, Alcon, Santen Pharmaceutical Co. Ltd., Shire/SAR code Bioscience, Otsuka Holdings

The global dry eye syndrome was valued around USD 2,200 million in 2017 and is expected to register CAGR of 5.2% in the forecast period.

Worldwide "Dry Eye Syndrome Industry" report gives essential examination to comprehend current market situation and future perspectives. The report assists with understanding Emerging Trends and Growth Opportunities alongside significant advancements in the Dry Eye Syndrome market.

Request customized copy of report@: https://straitsresearch.com/report/dry-eye-syndrome-market/request-sample

The reports cover key advancements in the Dry Eye Syndrome market as natural and inorganic development methodologies. Different organizations are zeroing in on natural development methodologies, for example, item dispatches, item endorsements and others like licenses and occasions. Inorganic development systems exercises saw in the market were acquisitions, and association and coordinated efforts. These exercises have cleared route for development of business and client base of market players. The market payers from Dry Eye Syndrome market are expected to rewarding development openings later on with the rising interest for Dry Eye Syndrome market in the worldwide market.

Key Players Influencing the Market: Allergan, Alcon, Santen Pharmaceutical Co. Ltd., Shire/SAR code Bioscience, Otsuka Holdings, Can-Fite Biopharma, Novartis, and Eyegate Pharma.

The report is segmented into the following categories: :

By Type, Evaporative Dry eye syndrome, Aqueous Dry eye syndrome

By Treatment Type, Nutritional Supplements, Serum Eye Drops, Lubricant Eye Drops, Oily Tear Eye Drops, Ointments, Preservative-Free drops, Anti-inflammatory drugs Segments, Tetracyclines, Corticosteroids

The report gives a point by point outline of the business including both subjective and quantitative data. It gives an outline and conjecture of the worldwide Dry Eye Syndrome market dependent on the kind and application. It additionally gives market size and figure till 2026 for by and large Dry Eye Syndrome market regarding five significant districts, in particular; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America (SAM). The market by every locale is later sub-divided by particular nations and sections. The report covers the investigation and figure of 18 nations all around the world alongside the latest thing and openings winning around there.

Answers that the report recognizes:

*Dry Eye Syndrome Market size and development rate during estimate period. *Key components driving the Dry Eye Syndrome Market. *Key market patterns laughing out loud the development of the Dry Eye Syndrome Market. *Difficulties to showcase development. *Key sellers of Dry Eye Syndrome Market. *Itemized SWOT investigation. *Openings and dangers faces by the current sellers in Global Dry Eye Syndrome Market. *Moving elements affecting the market in the topographical locales. *Key drives centering the main merchants. *Nuisance investigation of the market in the five significant locales.

Get Customized Research Dry Eye Syndrome Market Report at @https://straitsresearch.com/report/dry-eye-syndrome-market

Reasons to Purchase this report:

*To find out and give the latest measure of the Global Dry Eye Syndrome Market with respect to regard, result, by applications, types, and industry. *To purposely survey and profile key market players and comprehensively study their market position in regards to situating and competition, and nuances related to the vicious scene for the market bosses. *To calculate the gauge for the market similar to the value of various segments, by regions like North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW). *To give out unequivocal information related to the principle contemplations, drivers, restrainers, openings, and troubles influencing the Global Dry Eye Syndrome Market *Broad information about the market progression and creating business areas. The report moreover separates the market for various enhancements in different geographies. *To intentionally ponder and inspect smaller than normal business areas concerning solitary improvement examples, potential outcomes, and obligation to the overall Global Dry Eye Syndrome Market.

About Us:

Straits Research is a leading market research and market intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & market research reports.

For more details, please contact us -Straits Research

Address: 825 3rd Avenue, New York, NY 10022

Email: sales@straitsresearch.com

Tel:+1 646 480 7505

Website: https://straitsresearch.com

Media Contact

Company Name: Straitsresearch

Contact Person: aditya

Email: aditya.straitsresearch@gmail.com

Phone: 16464807505

Address:Address: 825 3rd Avenue, New York, NY, , 10022 New York, NY, USA, 10022

City: New York

State: United States

Country: United States

Website: https://straitsresearch.com/

Source: www.abnewswire.com

.

(C) 2021 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
ALCON INC. -0.81% 78.22 Delayed Quote.33.65%
OTSUKA HOLDINGS CO., LTD. -0.70% 4857 End-of-day quote.9.94%
SANTEN PHARMACEUTICAL CO., LTD. -2.99% 1620 End-of-day quote.-3.28%
All news about ALCON INC.
09/13ALCON : Wells Fargo Adjusts Alcon's Price Target to $93 from $90, Keeps Overweight Rating
MT
09/09ALCON : Morgan Stanley Raises Alcon's Price Target to $92 From $79, Sets Overweight Rating
MT
09/03ALCON : Optometry Reference Guide Creates New Category for Alcon's Permanent Water Surface..
PU
09/01ALCON : 2020 Corporate Responsibility Report
PU
08/27ANALYST RECOMMENDATIONS : Cummins, Dollar Tree, Five Below, HP, Workday...
08/24ALCON : Kepler Cheuvreux Lifts Price Target on Alcon
MT
08/23ALCON : Goldman Sachs Adjusts Price Target for Alcon to $91 From $83, Maintains Buy Rating
MT
08/23ALCON : Citigroup Adjusts Alcon's Price Target to $84 From $72, Maintains Neutral Rating
MT
08/23ANALYST RECOMMENDATIONS : Adobe, Baozun, Fafetch, Hydro One, Ontrak
08/20ALCON : DA Davidson Adjusts Price Target for Alcon to $87 From $77 on 'Attractive' Long-Te..
MT
More news
Analyst Recommendations on ALCON INC.
More recommendations
Financials (USD)
Sales 2021 8 141 M - -
Net income 2021 439 M - -
Net Debt 2021 2 699 M - -
P/E ratio 2021 96,5x
Yield 2021 0,13%
Capitalization 41 709 M 41 700 M -
EV / Sales 2021 5,45x
EV / Sales 2022 5,06x
Nbr of Employees 23 000
Free-Float 98,0%
Chart ALCON INC.
Duration : Period :
Alcon Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALCON INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 85,14 $
Average target price 87,29 $
Spread / Average Target 2,52%
EPS Revisions
Managers and Directors
David J. Endicott Chief Executive Officer & Director
Timothy C. Stonesifer Chief Financial Officer & Senior Vice President
F. Michael Ball Chairman
Franck Leveiller Head-Global Research & Development
Sue-Jean Lin Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
ALCON INC.33.65%41 700
THE COOPER COMPANIES, INC.17.46%21 041
AUTEK CHINA INC.37.92%10 616
MENICON CO., LTD.45.60%3 149
PEGAVISION CORPORATION97.88%1 411
UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.23.43%808